- Coordinator
- European Vaccine Initiative eV, Germany
- Runs
- 1 November 2023 to 30 April 2028
- Status
- Running
- EU funding
- €8.7m
- Total cost
- €8.7m
- Partners
- 9 organisations in 6 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101081028
What the project is doing
In the project's own words, from its summary on CORDIS.
Malaria remains a serious health concern worldwide, with P. falciparum considered one of the deadliest human parasites. Yet, the currently approved vaccine against malaria (RTS,S/AS01) offers limited protection due to challenges in vaccine development. Using current advances made in understanding immunity to address some of the existing challenges, this proposal aims to develop a more efficacious vaccine against P. falciparum by targeting multiple developmental stages (sporozoite, liver and blood-stage).
In this project, combinations of 1) highly promising whole parasite vaccination approach targeting the liver (late-arresting GAP), 2) RTS,S (provided by GSK) and 3) mRNA versions of clinically evaluated and partially protective blood stage vaccine candidates (Rh5, AMA1-DiCo [sporozoite and blood stage]) will be evaluated in preclinical and small-scale human trials to discern the optimal combination for further clinical investigations.
To inform a rational design of future vaccine candidates, CAPTIVATE will analyse the vaccine-induced immune response to acquire a full understanding of malaria protective immunity and develop an advanced immunology in-silico platform. While immunity to blood stage malaria is relatively well understood, the mechanisms of adaptive protective immunity for pre-erythrocytic malaria vaccine candidates are less well-established.
CAPTIVATE addresses this critical knowledge gap by combining state-of-the-art preclinical and clinical (CHMI) in vivo malaria vaccine efficacy models with an innovative in-silico platform comprising TCR/VDJ sequencing and artificial intelligence predictions, to identify such mechanisms. CAPTIVATE assembles a unique combination of European experts in their respective fields (malaria modelling in primates, clinical vaccine testing, in-silico modelling of immune responses, innovative omics approaches) in an integrated interdisciplinary approach aimed at bringing the next generation malaria vaccines to the clinic.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| European Vaccine Initiative eV | Heidelberg | Germany | Coordinator |
| University of New South Wales | Sydney | Australia | Associatedpartner |
| Immunewatch BV | Antwerpen | Belgium | Participant |
| Quantoom Biosciences | Nivelles | Belgium | Participant |
| Fyziologicky Ustav Akademie Ved Ceske Republiky Verejna Vyzkumna Instituce (vvi) | Praha 4 | Czechia | Participant |
| Deutsches Krebsforschungszentrum Heidelberg | Heidelberg | Germany | Participant |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| Stichting Biomedical Primate Research Center | Rijswijk Zh | Netherlands | Participant |
| Nec Oncoimmunity AS | Oslo | Norway | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI